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ABSTRACT 
Steroid radloimmunoassays (RIA) employ antibodies raised against a 
carrier protein-steroid conjugate. Individual antibodies may recognize 
the steroid, the protein or the chemical bridge used to join them 
together. Use of the same bridge in the tracer results in higher 
affinity binding of the tracer than the native ligand which in turn 
results in a loss of sensitivity and precision. We have greatly reduced 
bridge-binding in a RIA for androstenedione. Conjugates and radio- 
iodinated labels were prepared with either an ester OF ether chemical 
bridge. By using an antibody and the corresponding label with the 
heterologous bridge very sensitive assays were obtained. 
INTRODUCTION 
The major advantages of using Y-emitting radlonuclides such as 1251 
as opposed to tritium or other B-emitting radioisotopes to label tracers 
for steroid RIAs are: 1) the higher specific activity of they-emitting 
radiolabeled tracers (11, and 2) the ease and cost effective manner in 
which samples can be counted. The net effect of both of these factors 
is that more sensitive, less costly steroid assays are possible with 
Y-emitting tracers than with tritium based assays. The most serious 
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disadvantage to using radioiodinated labels arises from the affinity 
that the antibody may show not only for the hapten but for the bridge 
through which it was attached to the carrier protein. The recognition 
of the chemical bridge by the antibody has been refered to as bridge- 
binding (l-61. The problem arises when a radioiodinated histamine, 
tyrosine methyl ester or tyramine moiety is attached to the steroid 
through the same chemical bridge that was used to attach the hapten to 
the carrier protein in the immunogen. Because of the homology of the 
bridges, the antibody recognizes both the steroid and the bridge and 
will bind the tracer with a greater affinity than the steroid alone. 
Consequently, the amount of native antigen required to displace the 
radioiodinated tracer is so great that the standard curve is shifted to 
the right, the slope is extremely shallow, and a loss in sensitivity and 
precision results. In fact, assays using iodinated labels in which a 
bridge homologous to that in the immunogen is used are frequently much 
less sensitive than their tritiated counterparts (l-5). 
Several methods have been used to circumvent bridge-binding. 
Painter and Niswender (1,2) have shown in an e&radial-l@ assay that 
non-equilibrium assay conditions greatly increase sensitivity using a 
homologous label. However, this method employs a very short incubation 
(5-15 min) of antibody and label which could lead to technical problems. 
England & a (7) developed a RIA for estradiol-176 that employed 
antibody raised against lg-hydroxyestradiol-17 11-succinyl-bovine 
serum albumin (BSA) and lla-hydroxyestradiol-178 ll-succinyl-1251- 
iodotyrosine methyl ester label. The heterology resulting from the 
stereochemical differences between the a and fi linkages was such that 
the antibody did not recognize the succinate bridge of the trace. 
Unfortunately, this approach is not applicable for all steroid systems. 
For example, we have found that anti-lla-hydroq~ogesterone 
11-succinyl-BSA would not reoognlxe an iodinated derivative using ah 
118-bridge (8). Allen and Redshaw (5) introduced heterology by ahanging 
the chemical structure of the bridge in their labels. Unfortuuately, 
they were not able to accomplish one of the goals for using an lodinated 
trace, namely Increasing the assay sensitivfty relative to that possible 
through the use of the corresponding trltlated tracer. Niswender ( 2 ) 
recently reported on a RIA system for progesterone using a heterologous 
radloiodinated trace that alleviated bridge-binding and was more 
sensitive than an assay using tritiated progesterone. However, the 
reported 502 points are extremely high when compared to other assays 
(3,5). 
We wish to report a means of reducing antibody recognition of the 
tracer bridge by making subtle changes in the bridge adjacent to the 
steroid molecule. We used androstenedione (9) as a model and changed 
the commonly used succinyl ester linkage (-02CCH2CH2C02-steroid) to an 
ether functionality (-NHCOCH20-steroid). With this slight change a very 
sensitive RIA was obtained. 
MATERIALS 
Na112511 (carrier free) was obtained from New England Nuclear. 
C1,2,6,7-3Hl-4-androstene-3,17-dione (99 Ci/mmol) from Amersham was 
repurified on Sephadex LH-20 by elution with cyclohexane/benxene- 
/methanol (80/15/5). 19-Hydroxyandrostenedione was a gift from Searle 
Laboratories, Skokle, Ill. Ethyl chloroformate, ethyl diasoacetate, 
p-hydroxyphenylacetlc acid and tyramine were purchased from Aldrich 
Chemical Co. 1-Ethyl-3-(3-dimethylsminopropyl)-carbodiimide, dehydro- 
epiandrosterone, testosterone and 5o-dihydrotestosterone were obtained 
from Sigma Chemical Co. Chlorsmine-T and sodium metabisulfite were from 
J.T. Baker Co. Androstenedione, androsterone, Sa-androstanedione, 
progesterone and estradlol-17S were purchased from Steraloids In&, 
Wilton, N.H. Sephadex G-25 (fine mesh) and LH-20 were obtained from 
Pharmacia Fine Chemical. Pigskin gelatin was from Eastman Chemical, 
Merthiolate (Thimerosal) from Ruger Chemical Co., Irvington, N.J. and 
RhC13*3H20 was from Ventron Corporation. ACS scintillation fluid was 
obtained from Amersham. Solvents used were analytical grade. Steroids 
used as RIA standards and crossreactants were recrystalized. 
SYNTHESES 
The syntheses of conjugates and radioiodinated labels used in this 
study were prepared as outlined in figure 1. Melting points were 
determined in capillary tubes in a Thomas-Hoover apparatus and were 
corrected. Spectral analyses were obtained with the following instru- 
ments: IR, Perkin-Elmer 281; NMR, Varian EM-360; and UV, Cary 219. 
1Q-Hvdroxvm. The procedure __ _ _ 
of Bermudez & a (10) was used. A mixture of 19-hydroxyandrostenedione 
(1.0 gm, 3.31 mmol), succinic anhydride (1.0 gm, 10.0 mmol) and dry 
pyridine (10 ml) was stirred at room temperature in the dark for 7 days. 
The mixture was poured into 1 1 HCl (150 ml) and the pH adjusted to 1.0 
with concentrated HCl. The aqueous solution was then extracted five 
times with ethyl acetate (50 ml). The combined organic phase was dried 
over anhydrous Na2S04. Evaporation of the solvent u m yielded a 
clear oil (1.2 gm, 94%). Spectral data agreed with that reported 
previously (10). W (35 N,N-dimethylformamide (DMP)/H O), Xmax 245 nm 
(a=12,700): IR (CHC13), Yplax 3450, 1742 and 1670 cm -': NMR, p.p.m. 
(CD3COCD 1, 0.92 (s,3H,l8-Q3), 
63 
2.61 (s,4H,succinyl methylene-m, 4.31 
and 4.7 (dd J=l2.0 cps,2H,l9-CL+), 5.92 (s,lH,4-m, 8.00 (broad 
s,lH,-C02H, exchanged with D20). 
ene-3.17-w 'IQ-m-bova nm 
(m. II (100 mg, 0.25 mmol) was dissolved in DMP (10 ml) and H20 
(4 ml). I-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDAC) (100 mg, 
1.92 mmol) was added and the mixture stirred for 30 min. Bovine serum 
albumin (BSA) (200 mg) dissolved in phosphate buffer (0.02 J& pH 7.8, 
20 ml) was added dropwise to the steroid solution and stirred 4 days at 
room temperature in the dark. The solution was dialyzed against 0.05 M 
NaHC03 (2 x 2000 ml) and H20 (4 x 2000 ml) and subsequently dried by 
lyophilization. The molar ratio of the steroid to protein was found to 
be 9.2 by spectral analysis (11). 
D_dcetoxvDhenvlaoetic m m p-Hydroxyphenylacetic acid (36.0 
gm, 0.24 mol) was dissolved in acetic anhydride (130 gm, 1.26 mol) and 
concentrated H2SO4 (0.5 ml) added. The mixture was stirred overnight at 
room temperature and poured into Ii20 (800 ml). The solution was made 
basic with 1 1 NaOH and extracted five times with CHC13 (200 ml). The 
combined organic layer was dried with Na2S04 and the solvent removed u 
w yielding a white solid. Recrystalization from benzene gave 
p-acetoxyphenylacetic acid as white needles (34.7 gm, 76%) mp llO-lll°C. 
IR (CH2C12), ylnax 3500, 1765, 1720 and 1512 cm-'. 
p-Acetoxyphenylacetic acid (10.0 gm, 51.5 mmol) was dissolved in 
benzene (150 ml) and refluxed for 2 hr with a Dean-Stark apparatus to 
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Figure 1. Synthetio Schemes. 
remove H20. Thionyl chloride (2.2 ml) in benzene (30 ml) was added 
followed by the dropwise addition of pyridine (4.8 ml) in benzene (30 
ml). The resulting mixture was refluxed an additional 30 min, cooled to 
room temperature and poured into concentrated HCl (200 ml). Water (300 
ml) was added and the benzene layer removed, washed with H20, 1 H NaHC03 
and B20, and dried over Na2S04. R~OV~J of the solvent in PBPYP yielded 
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a yellow solid. Recrystalization from benzene gave IV as white needles 
(6.9 gm, 73%) mp 95-96'C. IR (CH$Q), yplax 1827, 1765 and 1512 cm": 
NMR, p.p.m. (CDCl3), 2.28 (s,~H,-C%CO~-), 3.28 (s,4H,pheny1-C&2CO-), 
7.18 (m,8H,phenyl-K). Anal. Cal& C2CH1807: C, 64.86; H, 4.90. Found: 
C, 65.07; H, 5.07. 
_ _ 3.17-m m 19-Hydroxy- 
androstenedione (1.0 gm, 3.31 mmol) and IV (2.0 gm, 5.40 mmol) were 
dissolved in dry pyridine (50 ml) and stirred in the dark at room 
temperature for 24 hr. The mixture was made acidic with 1 1 HCl and 
extracted 5 times with CHC13 (1000 ml). The combined organic layer was 
then washed with 100 ml H20, 1 L NaOH, H20 and 1 & HCl. The CHC13 was 
then dried over Na2S04 and evaporated in m yielding 19-(p-acetoxy- 
phenylacetoxy)-androstenedione as a yellow oil (1.55 gm, 98%). IR 
(CH2C12), Ymax 1740, 1671, and 1511 cm": NMR P.P.~. (CDC13), 0.88 (s, 
3H,l8-CH3), 2.28 (s,3H,CH3C02-), 3.60 (s,2H,phenyl-C&$X-), 4.20 and 
4.71 (dd J=l2.0 cps,2H,l9-ChO-), 5.86 (s,lH,4-&), 7.17 (m,4H,phenyl-&). 
19-(p-Acetoxyphenylacetoxy)-androstenedione (1.0 gm, 2.09 mmol) was 
dissolved in methanol (30 ml). Saturated aqueous NaHC03 solution (1 ml) 
was added and stirred for 12 hr at room temperature. The pH of the 
reaction mixture was adjusted to 2.0 with 0.5 1 HCl and extracted five 
times with CHC13. The chloroform layer was washed twice with H20 and 
dried. Removal of the solvent left a yellow oil that was purified on a 
3.8 x 45 cm silica gel column. Elution with benzene/ethyl acetate (4/l) 
yielded a clear oil. Recrystalixation from acetone/hexane produced V as 
a white solid (514 mg, 56%) mp 143.5-144'C. IR (CH2C12), Ymax 3590, 
1740, 1670 and 1520 cm": ), 3.50 
(s,2H,phenyl-CX2CO-), 
NMR, p.p.m. (CDC13), 0.85 (s,3H,l8-C 
7 4.15 and 4.65 (dd J=12.0 cps,2H,l9-C&O- , 5.85 
(s,lH,4-JU, 6.85 and 7.05 (dd J=lO.O cps,4H,phenyl-H), 7.75 (broad 9, 
lH,phenyliO& exchanged with D20). Anal. Calc. C27H32O5: C, 74.29; H, 
7.39. Found: C, 74.50; H, 7.56. 
Radioiodination nf L V (2.0 ug, 4.58 nmol) in CH30H (2~1) was placed 
in a 0.5 dram vial fitted with a multi-dose septum. Phosphate buffer 
(0.5 & pH 7.4, 40~1) and aqueous Na[125I] (4.0 mCi, 9.Oul) was added. 
The iodlnation was initiated by the addition of chloramlne-T (20 ug, 
71.0 nmol) in phosphate buffer (0.05 L pH 7.4, 20 111) (buffer A). 
After shaking at ambient temperature for 2 min the reaction was quenched 
by the addition of sodium metabisulfite (20 ug, 105 nmol) in buffer A 
(20 ul). The reaction mixture was transfered to a 0.9 x 22 cm Sephadex 
G-25 (fine mesh) column and eluted with buffer A to yield VI. The 
specific activity of the label was found to be 3.28 mCi/ ug using the 
method of Diekman at al (12). The maximal binding of the label (active 
fraction) in the presence of excess antibody was 99%. 
__ andraatene-l.l UIXL 19-HYdrow- 
androstenedione (100 mg, 0.33 -01) was dissolved in dry benzene (10 
ml). The catalyst Rh2(02CCH3)4 (1 lag), prepared from RhC13.3H20 (13), 
was added and the system Slushed with dry N2. Ethyl diasoacetate (1.09 
gm, 9.51 -01) was added dropwise to the steroid solution at 10°C. The 
reaction mixture was stirred for an additional 30 nin and poured Into 
820 (100 ml). The aqueous layer was extracted five times with CHCl3. 
The oombined organic layer was dried with Na2S04 and evaporated ip~ 
resulting in a yellow oil. Further purification on a 2 x 22 cm silica 
gel column eluted with a 0 to 25 
a clear oil (31 mg, 242). DV (3 
gradient in CHC13 yielded VII as 
/H20), Xmax 248 nm (s=13,400): IR 
(CHC13), yaaX 1740 and 1668 em- NMR, p.p.m. (CDCl ), 0.90 (s,3H, 
), 1.25 (t J=7.0 CpS,3H,-~H2C&+ 3.88 (q k7.0 ops,2H, 
3), 4.03 (s,2H,-02CC&$-), 4.10 and 4.45 (dd J=lO.O cps,ZH, 
19-C&#-), 5.90 (s,lH,4-&). Anal. Calc. C23H32O5 : C,71.11; Hp8.30. 
Found: C, 71.09; I&8.31. 
JQ-(C-3nndrastene-1.17-d -- tvIII]. VII (150 mg, 0.38 
mol) was dissolved in CH OH (10 ml). KOH (0.12 & 6.4 ml, 0.77 mpol) 
was added dropwise at 10 0% The reaction mixture was then poured into 
saturated NaCl solution (200 ml) and made acidic with 1 1 HCl. This 
solution uas extracted six times with CHC13 (10 ml). The organic phase 
was dried as above and evaporated invaouo yielding a clear oil (131 mg, 
941). IR (CHC13), ylnar 3400, 1738 and 1670 cm-‘: NMR, p.p.m. 
I;zgfs!s 4Pa,““,d,” 
3.75 and 3.95 (dd J=9.5 cps,EH, 
, 5.68 (s,lH,4-U. 7.53 (broad s,lH, 
-CO&exchanged with D20). 
_ _ __ 1.17- 
pipna UXL VIII (100 mg, 0.28 mol) was reacted with EDAC and BSA as 
detailed above for the formation of III. The molar ratio of steroid to 
protein was Sound to be 19.1 by W spectral analysis (11). 
_ _ _ __ 
3.17-u m VIII (50 mg, 0.28 ssnol) and triethylamlne (28 mg, 0.28 
nvnol) were dissolved In freshly distilled, dry tetrshydroiuran (THF) 
( 10 ml) and the mixture cooled to 2OC. Ethyl chloroformate (16.4 mg, 
0.16 lrmol) was added and stirred for 20 min. Tyramine (19.2 mg, 0.14 
mmol) dissolved in TIP/H20 (3/l) ( 15 ml) was added to the steroid 
solution and the pH of the reaction mixture adjusted to 8.5 with 1 1 
NaOH . ASter 16 hr the reaction mixture was poured into H20 (50 ml) and 
extracted five times with CHCl 
1. 
ASter drying with Na2S04 and removal 
of solvent in yacyp a yellow o 1 resulted. Final purification using a 
1.3 x 35 cun silica gel coluxn eluted with a 0 to 21 CH30H gradient in 
CHC13 yielded X as an oil (45 mg, 682). IR (CHC13), ylaax 3430 (amide 
N-E stretch), 3320, 1740 and 1670 cm-‘: N!!R, p.p.n. (CDC13), 0.90 
b,3WWd.3L 2.81 (t J=6.5 cps,2H,-NRCH2CK2-phenyl), 3.70 
(m,6H,-NRCU$H2-phenyl,-NRCOC&$-, and 19-C&0-), 5.88 (s,lH,4-B, 6.25 
(s,lH,-NNO-1, 7.08 and 7.28 (dd J-9.0 cps,4H,phenyl-&), 8.50 (broad 
s,lH,phenyl-OK, exchanged with D20). Anal. Calc. C2gH3705N: C, 72.62; 
H, 7.78. Found: C, 72.56; H, 7.99. 
RadioiodinationpfL X (2.0 pg, 3.88 nmol) was radioiodinated with the 
same procedure used to produce VI. The specific activity of XI was 
found to be 2.91 mCi/ ug and the active fraction 97%. 
METHODS 
D Antibodies against the ester-linked conjugate (III; 
A4-ester-BSA) and the ether-linked conjugate (IX; A4-ether-BSA) were 
raised in Suffolk ewes. Six animals were immunized with each immunogen. 
5.0 mg of conjugate in Freund's complete adjuvant (1.2 ml) was injected 
intradermally at multiple sites on the flanks of each animal. Booster 
injections of 2.0 mg in incomplete Freund's adjuvant (1.2 ml) were given 
at weeks 4, 8 and 12. Bleedings were taken at weeks 10, 11, 14 and 15. 
Serum was prepared by centrifugation and stored at -2OOC. The highest 
titers (dilution of serum required to bind 30% of the label) were found 
at week 11. Serum from the animal with the highest titer within each 
group at week 11 was used for the study. 
Radiaimmunoassav. The assay buffer used was 0.01 H sodium phosphate, 
0.14 M NaCl, 0.01% sodium merthiolate and 0.1% pigskin gelatin, pH 7.4 
(0.1% gel-PBS). Standard androstenedione (250 to 1 pg/tube) or cross- 
reactant steroids (1 pg to 12.5 pg/tube) dissolved in assay buffer was 
added to duplicate tubes as described previously (7). Antibody (200 
ul)(anti-A4-ester-BSA; 1/100,000 dilution for use with iodinated labels 
or l/10,000 dilution with tritiated androstenedione and anti-A4-ether- 
BSA; l/50,000 dilution for use with iodinated traces or l/4,000 dilution 
with tritium) in 0.1% gel-PBS + 0.05 g EDTA was added. FinallyJabel 
(100 p1)([3H]-androstenedione (A4-3H), 34 pg/16,000 cpm; VI 
(A4-ester-L), 6.8 pg/40,000 cpm; or XI (A4-ether-L), 7.5 pg/40,000 cpm) 
diluted in assay buffer was added. Triplicate total count, background 
and buffer control tubes contained 100 ~1 label, 100 ul label plus 700 
ul buffer or 100 1.11 label, 200 pl antibody plus 500 ul buffer 
respectively. Crossreactivity studies were done using the method of 
Thornycroft &al. (14). The assay tubes were vortexed and incubated at 
room temperature for 2 hr. Charcoal solution (1 ml)(O.25% charcoal and 
0.025% dextran in PBS buffer) was added for separation of bound label 
from free. The tubes were vortexed, incubated for 10 min at 4OC and 
centifuged at 800 x g for 15 min. The supernatants and total count 
tubes for the assays using iodinated labels were counted for 1 min in a 
Searle 1185 gamma counter. When tritiated label was employed the 
supernatants were added to scintillation fluid (10 ml) and counted for 4 
min in a Searle Isocap beta counter. Results were analyzed by computer 
as described elsewhere (15). 
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RRSDLTS AND DISCUSSION 
Figure 1 illustrates the structures of the ~o~~ate8 and 
rad~o~~~~ted labels used in thfa study. Althou@ the eater and ether 
brfdges are ohly slQ$btly different (the %at%r oarbohyl group is on% 
carbon at farther from the steroid molecul% than in the ether link- 
age), the difference was aufficieat to reduae bri~~b~~di~. St~d~d 
curve% were obtained using the antibodies against the eater-linlred 
ante-A~-%~ter-ESA) or ether-lihlced (aat~~A~~eth%r-BSA) locates and 
~~a$~~~ the amount of bound label (A&-eater-t, A+h%r-L or trftiated 
~dro~tenedione, A4-3R) in the presencle of vargirg ounts of 
androstehedione. The curve8 were linear whea logft-log tran~o~tion 
was employed. The total amount of label bound (no unlab%led steroid), 
the mount of unlabeled steroid needed to displaos 50% of the bound 
trace (50% point) and the slope of the standard ourve8 ar% shown in 
tabIe 1. 
The moat striking difference is the ch in aasay aermitivity uhen 
the ha~nologous aad hetarologous radfoiodfnated labels are compared, 
Antiwar-ester-~A used vith the heterologous A4-ether-L gave a 5Oj paint 
much lower (15 pg vsr 625 pg) than that obtained with the honrologous 
A4oe~teraL. As sxpeoted the total binding of the h l.qgowi label was 
greater (30.3% w 65.W). This trend WBB r%versed when anti-Aq-ether- 
BSA was used* C 425 pg vs, 76 pg and 62.4% bind&as V& 33.411). We we 
the 50% inhibzttion point for oomparfson in interaasay sensitivies be- 
cause it is ntuch mar% stable and provides an aocurate aomparisoo of 
ewe location. However, the actual limits of drrteotion (16) were rrhom 
to be 150-250 f~to~~8 for the A4-ethe~~aatfi-A~~eat~-~A omn- 
bimtion ttnd 0*9-l-1 pg iOr A4-esterr_llaati-a-eth~-~. 
Table 1 
DilutionkUlBindinn 
Anti-A4-ester-BSA l/lOO,OOOa A4-ether-Lb 30.3% 
n 1/100,000 A4-ester-LC 65.0% 
I( 1/10,000d A4-3He 32.3% 
Anti-A4-ether-BSA 1/50,000f A4-ether-L 62.4% 
” 1/50,000 All-ester-L 33.4% 
(I 1/4,ooog A4-3H 31.7% 
aFinal dilution; l/400,000 
b40,000 cpm; 7.5 &tube 
c40,000 cpm; 6.8 pg/tube 
dFinal dilution; l/40,000 
e16,000 cpm; 34 pg/tube 
fFinal dilution; l/200,000 
gFlna1 dilution; l/16,000 
15 pg/tube -1.64 
625 ” -0.72 
99 ” -2.32 
425 n -0.87 
76 ” -1.99 
128 ” -2.39 
Clearly the use of a heterologous bridge drastically decreases 
bridge-binding and increases sensitivity. Another important advantage 
of using a heterologous label is the increased slope of the standard 
curve. As the magnitude of the slope approaches the value obtained 
using a tritiated tracer it indicates that the affinity of the antibody 
for the tracer and the native steroid are more nearly similar and 
relatively less native antigen is required to inhibit binding of the 
label. The steeper slope yields a more precise assay because less mass 
of standard is required to elicit an equivalent change in % binding and 
the percent of radiolabeled tracer bound to the antibody can be in- 
creased without unacceptable losses of sensitivity. This study also 
demonstrates that the use of a heterologous trace can yield an assay 
that is more sensitive than one in which tritiated labels are employed 
(50% point of 15 pg vs. 99 pg for anti-A4-ester-BSA and 76 pg vs. 128 pg 
for anti-A4-ether-BSA). An additional advantage is the higher dilution 
of antibody used in assays employing radioiodinated traces. In both 
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oases the antibody dilution used with the radioiodiuated label was at 
least lo-fold greater than that used with tritium. Crossreaotivities of 
both antisera with other steroids are shown in table 2. 
Table 2 
Androstenedione 100.0 100.0 
5a-Androstanedione 52.2 61.7 
19-Iiydroxyandrostenedione 25.3 26.5 
Testosterone 0.05 0.3 
5a-Dihydrotestosterone 0.04 0.1 
Dehydroepiandrosterone 26.0 10.0 
Androsterone 48.1 34.8 
Progesterone 0.03 0.1 
Estradiol-175 0.1 0.08 
The crossreactivity of 5a-androstanedione was not unexpected. 
Antibodies apparently can not differentiate between the 4-ene and 5a- 
reduced forms of androgens (10,17-19). Likewise, the crossreactivity of 
the 19-hydroxyandrostenedione was expected since the conjugates were 
made from this compound (19). However, in addition to the problem of 
recognizing 5a-androstanedione and the 19-hydrory compound the 
antibodies bound dehydroepiandrosterone and androsterone. These 
steroids possess 3B-hydroxy-5-ene and 3r-hydroxy+x-dihydro 
funotionalities respeotively which are quite different from the 
3-oxo-Gene configuration of androstenedione. Apparently when 
androstenedione is conjugated to the carrier protein through the 19 
position, the A-ring of the steroid, in particular the 3 position, may 
be partially enveloped by the carrier protein and consequently the 
antibodies do not distinguish between 3-0~0 or 3-hydroxy steroids. This 
Phenomenon has been seen recently for other 19-ester (10) or 19-ether 
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linked (20) androstenedlone conjugates. In spite of the 
crossreaotivities with the !?u-reduced and 3-hydroxy steroids the 
19-androstenedione system is a good model for demonstrating the 
existence of bridge-binding and a method for reducing it. We have shown 
that through the use of a heterologous radioiodinated label a very 
precise and sensitive assay can be obtained, and in addition, the 
sensitivity is greater than in assays that utilize t&Mated traces. 
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